Belfast-based Re-Vana Therapeutics raises $11.9m
Queen’s spin-out is developing therapeutics for the treatment of vision-threatening ocular diseases
Re-Vana Therapeutics, a spin-out company from Queen's University Belfast focused on improving treatment of chronic eye diseases, has raised $11.9 million (€11.4 million) in an oversubscribed Series A funding round that saw the firm securing an additional $4 million than originally targeted.
Founded in 2016, Re-Vana is a speciality drug delivery company developing sustained-release therapeutics for the treatment of vision-threatening ocular diseases. The spin-out, which previously raised nearly $6 million from investors, is to use ...